Y-mAbs Therapeutics, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

The Complaint claims that the Company, Y-mAbs, made false and misleading statements to the market. Y-mAbs allegedly deceived investors by stating that they were making progress in showing the effectiveness and efficacy of their drug candidate, omburtamab, during meetings with the FDA. However, in reality, the FDA had advised the Company that it could not compare data from its studies with the Central German Childhood Cancer Registry (CGCCR) database due to various reasons, including the absence of tumor response data. The Company also failed to inform investors that it had decided to submit its BLA on March 31, 2022, before reaching an agreement with the FDA. Due to these false statements, investors incurred damages when the truth was revealed.